Gilead Sciences has agreed to acquire Arcellx in a deal valued at $7.8 billion, causing Arcellx’s stock to surge 78% before the market opened. This acquisition marks a significant move for Gilead in the biotech sector.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.
Gilead Sciences has agreed to acquire Arcellx in a deal valued at $7.8 billion, causing Arcellx’s stock to surge 78% before the market opened. This acquisition marks a significant move for Gilead in the biotech sector.